CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This activity is intended for medical oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of myelofibrosis.
  
  LEARNING OBJECTIVES

  • Use an understanding of disease biology and natural history to accurately diagnose myelofibrosis and effectively counsel patients diagnosed with these disorders regarding long-term prognoses.
  • Analyze how age, performance status, prior therapeutic exposure and other biological and disease-related factors affect the selection and sequencing of therapy for patients with primary and secondary myelofibrosis.
  • Appraise available research findings informing the safety and efficacy of approved JAK inhibitors in patients with myelofibrosis, including those with thrombocytopenia, anemia or compromised renal function.
  • Review available research data with and the current clinical role of novel JAK inhibitors for patients with myelofibrosis and severe thrombocytopenia.
  • Evaluate available research findings with investigational JAK inhibitors for patients with myelofibrosis and anemia in preparation for the potential commercial availability of additional therapeutic alternatives for this patient population.
  • Consider evidence-based therapeutic options for polycythemia vera (PV) and essential thrombocythemia (ET), and develop clinical algorithms intended to enhance quality and quantity of life for patients with these distinct yet related diseases.
  • Develop supportive care plans to more effectively monitor for, identify and manage side effects and toxicities associated with commonly utilized agents for myelofibrosis, PV and ET.
  • Recall the biological rationale for, available efficacy and safety data with and design of ongoing clinical trials evaluating novel investigational agents and strategies for patients with myelofibrosis, PV and ET, and refer eligible patients for study participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  Audio Program: Research To Practice designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  Video Program: Research To Practice designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  Successful completion of these CME activities, which includes participation in the evaluation components and short post-tests, enables the participant to earn up to 1.75 (audio) and 1.25 (video) Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for each activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  
  Please note, these programs have been specifically designed for the following ABIM specialties: medical oncology and hematology.
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  To receive credit for an activity in this series, the participant should review the CME information, listen to or view the MP3s, review the downloadable slide set, complete the post-test with a score of 80% or better and fill out the evaluation. Program location URLs are noted below:
  
  Audio Program: ResearchToPractice.com/OncologyTodayPostASH24/MPN and evaluation ResearchToPractice.com/OncologyTodayPostASH24/MPN/CME.
  
  Video Program: ResearchToPractice.com/OncologyTodayPostASH24/MPN/Video and evaluation ResearchToPractice.com/OncologyTodayPostASH24/MPN/Video/CME.
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Naveen Pemmaraju, MD
  Professor, Department of Leukemia
  Executive Director, Cancer Medicine
  Director, Blastic Plasmacytoid Dendritic Cell Neoplasm Program
  The University of Texas MD Anderson Cancer Center
  Houston, Texas
  
  Consulting Agreements: AbbVie Inc, Aptitude Health, Astellas, Blueprint Medicines, Bristol Myers Squibb, CareDx, Celgene Corporation, Cimeio Therapeutics, ClearView Healthcare Partners, CTI Biopharma, a Sobi company, Curio Bioscience, DAVA Oncology, EUSA Pharma, iMedX, ImmunoGen Inc, Intellisphere Oncology Specialty Group, Menarini Group, NeoPharm Inc, Novartis, Pacylex Pharmaceuticals Inc, PharmaEssentia; Data and Safety Monitoring Board/Committee: NS Pharma Inc; Nonrelevant Financial Relationships: Cancer.Net, Harborside Press, Karger Publishers, Magdalen Medical Publishing Ltd, Medscape, OncLive, Patient Power, PeerView Institute for Medical Education, Physician Education Resource (PER), National Institutes of Health/National Cancer Institute, The Aplastic Anemia and MDS International Foundation, US Department of Defense.
  
  EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI Biopharma, a Sobi company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from CTI Biopharma, a Sobi company, and Incyte Corporation.
  
  Release date: April 2024
  Expiration date: April 2025
  
  After completing the post-test, learners may download and review the answers here in order to identify further areas of study.